Merck & Co., Inc.
NYSE: MRK
$83.38
+$1.21 (+1.5%)
Closing price January 15, 2021
The 2021 Dogs of the Dow are now known, and investors who may want to follow this investing strategy have got some thinking to do.
18 days ago
Six Dow stocks are on track to lose at least 10% of their value in 2020. Here's a look at what's happened.
20 days ago
Last Updated: 19 days ago
One popular investment strategy, known as the Dogs of the Dow, has performed better than last year. What's ahead for the dogs in 2021?
27 days ago
Rotating from overbought and crowded momentum stocks makes sense now. From a total return standpoint, dividend-paying large-cap pharmaceutical stocks may be one of the best ideas for 2021.
1 month ago
COVID-19 stocks were on the move on Wednesday after a few huge updates in regards to vaccine approval.
1 month ago
Merck has joined the fight against COVID-19 by acquiring OncoIummune in an all-cash transaction.
1 month ago
Some rather significant changes were made in the Berkshire Hathaway equity portfolio during the third quarter.
2 months ago
Last Updated: 2 months ago
Merck and Pfizer reported their most recent quarterly results before the opening bell Tuesday, and investors were not thrilled about this quarter for these two pharmaceutical giants.
2 months ago
Roughly a third of the Dow Jones industrial average components are scheduled to report their latest quarterly reports this week.
2 months ago
Health care is one sector that continues to draw a ton of fund manager interest, and with good reason. These five dividend-paying health care stocks are all favored by large-cap portfolio managers.
3 months ago
Tuesday's top analyst upgrades and downgrades included AbbVie, CSX, Dominion Energy, JPMorgan, NXP Semiconductors, ONEOK, Pfizer, Square, United Parcel Service and WPX Energy.
3 months ago
Last Updated: 3 months ago
These five dividend-paying large-cap pharmaceutical stocks look like outstanding ideas for nervous investors looking for income and a degree of safety. They have come way in from their 52-week...
4 months ago
Tuesday's top analyst upgrades and downgrades included Crocs, Gap, GW Pharmaceuticals, Lowe's Companies, Merck, Nio, Palo Alto Networks, Phillips 66, Starbucks and Vital Farms.
4 months ago
Last Updated: 4 months ago
24/7 has compiled a few biopharmaceutical names that have lagged the markets and recently have reported earnings. In a sense, the fundamentals have shown some light on these stocks, that they may be...
5 months ago
Last Updated: 5 months ago
Monday's top analyst upgrades and downgrades included AbbVie, DuPont, Etsy, Expedia, Exxon Mobile, Kansas City Southern, Merck, Microsoft, Pinterest, Qualcomm, Visa and Yum! Brands.
5 months ago
Last Updated: 5 months ago